Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Authors :: Abdulraheem Yacoub
Uma Borate
Raajit K Rampal
Haris Ali
Eunice Wang
Aaron T. Gerds
Gabriela S. Hobbs
Marina Kremyanskaya
Elliott Winton
Casey O'Connell
Swati Goel
Stephen T Oh
Gary J. Schiller
Albert Assad
Sue Erickson-Viitanen
Feng Zhou
Naval Daver
Source :: Blood. 140:579-582
Publication Year :: 2022
Publisher :: American Society of Hematology, 2022.

Tools